Strata Critical Medical (Nasdaq: SRTA) lifts 2026 revenue and EBITDA guidance

Q: How did Strata Critical Medical (SRTA) perform financially in Q2 2026?

Strata reported Q2 2026 revenue of $72.5 million , up 60.7% year-over-year, and a net loss from continuing operations of $10.5 million . Gross profit was $15.2 million and Adjusted EBITDA increased to $7.9 million with a 10.9% margin.

Q: What drove revenue growth for Strata Critical Medical (SRTA) in Q2 2026?

Revenue growth was led by Logistics revenue of $48.2 million , up 6.9% year-over-year, and Clinical revenue of $24.3 million . Clinical grew 22.6% sequentially, helped by Transplant Clinical and Other Clinical services plus acquisitions completed during Q2 2026.

Q: What is Strata Critical Medical’s (SRTA) 2026 financial guidance?

For 2026, Strata guides to revenue of $285–295 million and Adjusted EBITDA of $33–35 million . It also targets free cash flow before aircraft and engine acquisitions of $15–22 million , and provides higher pro forma ranges assuming all 2026 acquisitions closed January 1.

Q: How profitable was Strata Critical Medical (SRTA) on an Adjusted EBITDA basis in Q2 2026?

Strata generated Q2 2026 Adjusted EBITDA of $7.9 million , up from $2.5 million a year earlier. The Adjusted EBITDA margin improved to 10.9% , compared with 5.5% in Q2 2025, reflecting higher gross profit and lower Adjusted SG&A as a percentage of revenue.

Q: What acquisitions did Strata Critical Medical (SRTA) complete around Q2 2026?

During Q2 2026, Strata acquired Ohio Valley Perfusion Associates , Louisville Perfusion Services and Heart and Lung Transplant National Recovery Program . In late July 2026, it also signed an agreement to assume Statline’s Transplant Center Organ Placement customer relationships.

Q: What is Strata Critical Medical’s (SRTA) cash and liquidity position after Q2 2026?

At June 30, 2026, Strata held $16.3 million in cash and equivalents and $6.4 million in short-term investments . Q2 2026 cash flow from operating activities was $5.7 million, and Free Cash Flow, before aircraft and engine acquisitions, was $2.9 million.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Strata Critical Medical, Inc. reported Q2 2026 revenue of $72.5 million, up 60.7% from Q2 2025, driven by 6.9% Logistics growth and the addition of Clinical services. Clinical revenue reached $24.3 million, up 22.6% sequentially, with Transplant Clinical up 27.3% and Other Clinical up 18.1% versus Q1 2026. Results reflect continuing operations after divesting the Passenger business.

Gross profit rose 68.9% to $15.2 million, lifting gross margin to 21.0%. Net loss from continuing operations widened to $10.5 million, or 14.5% of revenue, while Adjusted EBITDA increased to $7.9 million with a 10.9% margin. Operating cash flow was $5.7 million and Free Cash Flow was $2.9 million in Q2, with cash and cash equivalents of $16.3 million and short-term investments of $6.4 million at June 30, 2026. The company closed three bolt-on Clinical acquisitions and updated 2026 guidance to revenue of $285–295 million and Adjusted EBITDA of $33–35 million, both higher than prior ranges.

Positive

Strong top-line growth: Q2 2026 revenue was $72.5 million, a 60.7% increase over Q2 2025, with Clinical services becoming a significant contributor.
Profitability improving on an adjusted basis: Q2 2026 Adjusted EBITDA rose to $7.9 million with a 10.9% margin, up from $2.5 million and 5.5% a year earlier.
Guidance raised: 2026 revenue guidance increased to $285–295 million (from $260–275 million) and Adjusted EBITDA to $33–35 million (from $29–33 million), reflecting confidence in growth and acquisitions.

Negative

Losses widened: Q2 2026 net loss from continuing operations reached $10.5 million, or 14.5% of revenue, compared with $3.4 million, or 7.6%, in Q2 2025.

Filing Explained

Completed acquisitions used cash, issued common stock, and added payable obligations, diluting existing holders and reducing available liquidity.

Form 8-K reports specified material events, and this filing furnishes Strata’s completed second-quarter results while identifying acquisition funding that affects existing holders. The completed acquisitions used $34,823 thousand of cash and included common stock issuance and additional consideration payable.

The balance sheet reports 88,466,806 common shares issued at June 30, 2026, versus 86,702,183 at December 31, 2025, and the cash-flow disclosures identify $4,267 thousand of common stock issued for an acquisition. Issuing additional shares increases the share count and reduces an existing holder’s percentage ownership absent offsetting changes.

The acquisitions also produced $2,950 thousand of consideration payable in other current liabilities, while cash and short-term investments totaled $22.8 million at quarter-end; the filing therefore documents both completed expansion and the associated cash, equity, and near-term payment mechanics.

Separately, Strata signed an agreement in late July to take over Statline’s Transplant Center Organ Placement customer relationships on a rolling basis over the next year, with up to eight new customers described as potential attachment points rather than completed transfers.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Revenue: $72,506 thousand Q2 2026 Gross profit: $15,215 thousand Q2 2026 Net loss from continuing operations: $(10,516) thousand +5 more

8 metrics

Q2 2026 Revenue $72,506 thousand Three months ended June 30, 2026; 60.7% above Q2 2025

Q2 2026 Gross profit $15,215 thousand Three months ended June 30, 2026; 68.9% above Q2 2025

Q2 2026 Net loss from continuing operations $(10,516) thousand Three months ended June 30, 2026; loss margin 14.5% of revenue

Q2 2026 Adjusted EBITDA $7,887 thousand Three months ended June 30, 2026; 219.8% above prior year

Q2 2026 Adjusted EBITDA margin 10.9 % Adjusted EBITDA as a percentage of revenue in Q2 2026

Cash and cash equivalents $16,317 thousand Balance at June 30, 2026 on condensed consolidated balance sheet

Short-term investments $6,436 thousand Balance at June 30, 2026 on condensed consolidated balance sheet

2026 revenue guidance range $285–295 million Updated full-year 2026 revenue guidance, increased from $260–275 million

Key Terms

Adjusted EBITDA, Free Cash Flow before aircraft and engines acquisitions, normothermic regional perfusion, organ procurement organizations, +2 more

6 terms

Adjusted EBITDA financial

"Strata reports Adjusted EBITDA, which is a non-GAAP financial measure."

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

Free Cash Flow before aircraft and engines acquisitions financial

"Free Cash Flow before aircraft and engines acquisitions highlights the cash generated"

normothermic regional perfusion medical

"core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion"

Normothermic regional perfusion is a medical technique that temporarily restores warm blood flow to specific organs after a patient’s circulation has stopped, keeping the organs alive and functional until they can be removed for transplant. For investors, it matters because the method can increase the number and quality of transplantable organs, creating demand for specialized equipment, supplies and services and potentially affecting regulatory approvals, reimbursement and market growth in transplant-related technologies.

organ procurement organizations medical

"partner to the hospitals, transplant centers and organ procurement organizations we serve"

Organ procurement organizations coordinate the identification, recovery and distribution of donated organs for transplantation, acting like a logistics and quality-control center that connects donors, hospitals and transplant teams. They matter to investors because their performance, rules and funding levels directly influence the supply and timing of transplantable organs, which affects demand for surgical services, medical devices, diagnostics and related healthcare revenues and regulatory risk.

held-to-maturity investments financial

"Accretion of interest income on held-to-maturity securities"

contingent consideration financial

"Represents contingent consideration in connection with the Keystone acquisition"

Contingent consideration is an additional payment agreed when one company buys another that will be paid later only if specific future targets are met, such as revenue, profit, or regulatory milestones. It matters to investors because it shifts risk between buyer and seller and affects the acquiring company's future cash flow and reported value — like promising a bonus after results are proven.

Earnings Snapshot

Revenue: $72,506 thousand · Guidance included

Three months ended June 30, 2026

Revenue $72,506 thousand 60.7% increase vs Q2 2025

Gross profit $15,215 thousand 68.9% increase vs Q2 2025

Net loss from continuing operations $(10,516) thousand 208.5% higher loss vs Q2 2025

Adjusted EBITDA $7,887 thousand 219.8% increase vs Q2 2025

Guidance

For 2026, revenue guidance is $285–295 million and Adjusted EBITDA guidance is $33–35 million, with free cash flow before aircraft and engine acquisitions of $15–22 million. Pro forma, revenue would be $295–305 million and Adjusted EBITDA $36–38 million assuming 2026 acquisitions closed January 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 08/04/2026 - 07:14 AM Accepted by SEC EDGAR 08/04/2026 - 07:13 AM

FAQ

How did Strata Critical Medical (SRTA) perform financially in Q2 2026?

Strata reported Q2 2026 revenue of $72.5 million, up 60.7% year-over-year, and a net loss from continuing operations of $10.5 million. Gross profit was $15.2 million and Adjusted EBITDA increased to $7.9 million with a 10.9% margin.

What drove revenue growth for Strata Critical Medical (SRTA) in Q2 2026?

Revenue growth was led by Logistics revenue of $48.2 million, up 6.9% year-over-year, and Clinical revenue of $24.3 million. Clinical grew 22.6% sequentially, helped by Transplant Clinical and Other Clinical services plus acquisitions completed during Q2 2026.

What is Strata Critical Medical’s (SRTA) 2026 financial guidance?

For 2026, Strata guides to revenue of $285–295 million and Adjusted EBITDA of $33–35 million. It also targets free cash flow before aircraft and engine acquisitions of $15–22 million, and provides higher pro forma ranges assuming all 2026 acquisitions closed January 1.

How profitable was Strata Critical Medical (SRTA) on an Adjusted EBITDA basis in Q2 2026?

Strata generated Q2 2026 Adjusted EBITDA of $7.9 million, up from $2.5 million a year earlier. The Adjusted EBITDA margin improved to 10.9%, compared with 5.5% in Q2 2025, reflecting higher gross profit and lower Adjusted SG&A as a percentage of revenue.

What acquisitions did Strata Critical Medical (SRTA) complete around Q2 2026?

During Q2 2026, Strata acquired Ohio Valley Perfusion Associates, Louisville Perfusion Services and Heart and Lung Transplant National Recovery Program. In late July 2026, it also signed an agreement to assume Statline’s Transplant Center Organ Placement customer relationships.

What is Strata Critical Medical’s (SRTA) cash and liquidity position after Q2 2026?

At June 30, 2026, Strata held $16.3 million in cash and equivalents and $6.4 million in short-term investments. Q2 2026 cash flow from operating activities was $5.7 million, and Free Cash Flow, before aircraft and engine acquisitions, was $2.9 million.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 4, 2026

Date of Report (date of earliest event reported)

___________________________________

STRATA CRITICAL MEDICAL, INC.

(Exact name of registrant as specified in its charter)

___________________________________


Delaware (State or other jurisdiction of incorporation or organization)	001-39046 (Commission File Number)	84-1890381 (I.R.S. Employer Identification Number)
666 Third Avenue, 25th Floor New York, NY 10017
(Address of principal executive offices and zip code)
(917) 781-3190
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SRTA	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) .

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 4, 2026, Strata Critical Medical, Inc. (“Strata”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

This information is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits

(d) The following exhibits are being filed herewith:


Exhibit No.						Description
99.1						Press Release, dated August 4, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STRATA CRITICAL MEDICAL, INC.

Dated: August 4, 2026

By:

/s/ William A. Heyburn

Name:

William A. Heyburn

Title:

Co-Chief Executive Officer and Chief Financial Officer

Exhibit 99.1

August 4, 2026

Strata Critical Medical Announces Second Quarter 2026 Results

•Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026

•Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clinical revenue increased 15.1% sequentially driven by a 23.8% increase in Transplant Clinical revenue

•Q2 2026 net loss from continuing operations of $(10.5) million or (14.5)% of revenue

•Adjusted EBITDA(1) of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9%

•Cash flow from operating activities was $5.7 million in Q2 2026; Free Cash Flow(1) was $2.9 million in Q2 2026

•Completed bolt-on acquisitions of Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program and Ohio Valley Perfusion Associates during Q2 2026

•Signed agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year

NEW YORK — (August 4, 2026) — Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the second quarter ended June 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only. The results of the divested Passenger business have been reclassified as discontinued operations in all periods.

GAAP FINANCIAL RESULTS

(in thousands except percentages, unaudited)


	Three Months Ended June 30,								Six Months Ended June 30,
	2026			2025			% Change		2026			2025			% Change
Revenue:
Logistics	$	48,240		$	45,108		6.9	%	$	95,839		$	81,056		18.2	%
Transplant Clinical	12,521			—			NM(2)		22,360			—			NM(2)
Other Clinical	11,745			—			NM(2)		21,691			—			NM(2)
Total Clinical	24,266			—			NM(2)		44,051			—			NM(2)
Total revenue	$	72,506		$	45,108		60.7	%	$	139,890		$	81,056		72.6	%
Gross profit:
Logistics	$	8,888		$	9,007		(1.3)	%	$	18,053		$	16,060		12.4	%
Clinical	6,327			—			NM(2)		11,279			—			NM(2)
Total gross profit	$	15,215		$	9,007		68.9	%	$	29,332		$	16,060		82.6	%




Gross margin	21.0		%	20.0		%	100	bps	21.0		%	19.8		%	120	bps

Selling, general and administrative	$	13,996		$	13,292		5.3	%	$	29,601		$	25,622		15.5	%
Amortization of intangible assets	6,627			356			1,761.5	%	8,113			764			961.9	%

Total operating expenses	$	20,623		$	13,648		51.1	%	$	37,714		$	26,386		42.9	%
Operating loss from continuing operations	$	(5,408)		$	(4,641)		16.5	%	$	(8,382)		$	(10,326)		(18.8)	%
Net loss from continuing operations	$	(10,516)		$	(3,409)		208.5	%	$	(8,114)		$	(5,021)		61.6	%
Net loss from continuing operations as a percentage of revenue	(14.5)		%	(7.6)		%	(690	bps)	(5.8)		%	(6.2)		%	40	bps

(1) See "Use of Non-GAAP Financial Information" and "Key Metrics and Non-GAAP Financial Information" sections attached to this release for an explanation of Non-GAAP measures used and reconciliations to the most directly comparable GAAP financial measure.

(2) Not meaningful.

NON-GAAP(1) FINANCIAL RESULTS

(in thousands except percentages, unaudited)


	Three Months Ended June 30,								Six Months Ended June 30,
	2026			2025			% Change		2026			2025			% Change
Revenue:
Logistics	$	48,240		$	45,108		6.9	%	$	95,839		$	81,056		18.2	%
Transplant Clinical	12,521			—			NM(2)		22,360			—			NM(2)
Other Clinical	11,745			—			NM(2)		21,691			—			NM(2)
Total Clinical	24,266			—			NM(2)		44,051			—			NM(2)
Total revenue	$	72,506		$	45,108		60.7	%	$	139,890		$	81,056		72.6	%
Gross profit:
Logistics (3)	$	8,888		$	9,007		(1.3)	%	$	18,053		$	16,060		12.4	%
Clinical (4)	6,327			—			NM(2)		11,279			—			NM(2)
Total gross profit	$	15,215		$	9,007		68.9	%	$	29,332		$	16,060		82.6	%

Gross margin:
Logistics	18.4		%	20.0		%	(160	bps)	18.8		%	19.8		%	(100	bps)
Clinical	26.1		%	—		%	NM(2)		25.6		%	—			NM(2)
Total gross margin	21.0		%	20.0		%	100	bps	21.0		%	19.8		%	120	bps

Adjusted SG&A	$	9,115		$	7,393		23.3	%	$	18,329		$	14,785		24.0	%
Adjusted SG&A as a percentage of revenue	12.6		%	16.4		%	(380	bps)	13.1		%	18.2		%	(510	bps)





Adjusted EBITDA	$	7,887		$	2,466		219.8	%	$	14,297		$	2,882		396.1	%
Adjusted EBITDA as a percentage of revenue	10.9		%	5.5		%	540	bps	10.2		%	3.6		%	660	bps

(2) Not meaningful.

(3) Net of depreciation expense of $1,417 and $852 for the three months ended June 30, 2026 and 2025, respectively, and $2,564 and $1,607 for the six months ended June 30, 2026 and 2025, respectively.

(4) Net of depreciation expense of $370 and $730 for the three and six months ended June 30, 2026, respectively.

"Our strategic expansion into clinical services is running well ahead of schedule after our accelerated progress on both organic growth and M&A execution in Q2," said Will Heyburn, Co-CEO and CFO. "Year-to-date, we've completed three acquisitions that have significantly expanded our footprint and operational efficiency while adding more than $6 million of projected annualized Adjusted EBITDA at our targeted mid-single-digit acquisition multiples."

Heyburn continued, "With each quarter, more of the financial benefits of our strategic execution shine though, with Q2 posting records for revenue, operating cash flow and free cash flow driven by strong overall performance and standout results in our Transplant Clinical business line, which grew 24% quarter-over-quarter versus Q1 2026. Looking forward, we're left with a business that is higher margin and less capital intensive as a result."

"Following our significant growth and successful acquisition integration, Strata is a stronger, more capable and more cost effective partner to the hospitals, transplant centers and organ procurement organizations we serve," said Melissa Tomkiel, Co-CEO and General Counsel. "Our broader geographic footprint means our clinicians spend more time in operating rooms and less time on airplanes, reducing the bill for customers and maximizing the productivity of our surgeons and perfusionists."

Tomkiel continued, "We are now able to leverage expanded local resources to make our service less costly and more reliable. At the same time, we've diversified our business and increased our exposure to the fastest growing parts of the transplant ecosystem: third-party surgical recovery and NRP. I'm more confident now than ever in our long-term strategy."

Second Quarter Ended June 30, 2026 Financial Highlights: Q2 2026 vs. Q2 2025

▪Total revenue increased 60.7% to $72.5 million in Q2 2026 versus $45.1 million in the prior year period driven by organic growth in Logistics, the addition of our Clinical business through the acquisition of Keystone in Q3 2025 and the contribution from Clinical acquisitions completed during Q2 2026.

▪Logistics revenue, which represents the Company's organic revenue growth, increased 6.9% to $48.2 million in Q2 2026 versus $45.1 million in the prior year period driven primarily by higher Air revenue. Compared to the year ago period, strength in Organ Procurement Organization customers and softness in Transplant Center customers drove shorter trip distances, muting overall revenue in the period. The Clinical business continued to drive growth in Logistics revenue compared to the prior year period.

▪Gross profit increased 68.9% to $15.2 million in Q2 2026 versus $9.0 million in the prior year period driven by the addition of our Clinical business and the contribution from Clinical acquisitions completed during Q2 2026, partially offset by a modest decline in Logistics gross profit.

▪Gross margin increased 100 basis points to 21.0% in Q2 2026 versus 20.0% in the prior year period driven primarily by the positive mix impact from the addition of our Clinical business and the contribution from Clinical acquisitions completed during Q2 2026, partially offset by a decline in Logistics gross margin.

▪Logistics gross profit decreased 1.3% to $8.9 million in Q2 2026 versus $9.0 million in the prior year period. Logistics gross margin of 18.4% in Q2 2026 decreased 160 basis points versus 20.0% the prior year period driven primarily by an increase in the fuel surcharge, fuel costs, customer mix, modestly lower owned fleet profitability and lower ground margins.

Given that the acquisition of our Clinical business as well as the sale of our Passenger business occurred in Q3 2025, and the recent Clinical acquisitions completed during Q2 2026, year-over-year comparisons of Clinical metrics, Net Income, Adjusted SG&A, Adjusted EBITDA and cash flow are not meaningful. Please see below for sequential comparisons for these metrics.

Second Quarter Ended June 30, 2026 Financial Highlights: Q2 2026 vs. Q1 2026

▪Clinical revenue rose 22.6% to $24.3 million in Q2 2026 versus $19.8 million in Q1 2026. Excluding Clinical acquisitions completed during Q2 2026, Clinical revenue rose 15.1% in Q2 2026 versus Q1 2026 driven primarily by Transplant Clinical revenue, which rose 23.8% and Other Clinical revenue, that rose 6.5%.

▪Clinical gross profit increased 27.8% to $6.3 million in Q2 2026 versus $5.0 million in Q1 2026. Clinical gross margin increased to 26.1% in Q2 2026 versus 25.0% in Q1 2026.

▪Total Selling, General and Administrative expenses decreased $1.6 million to $14.0 million in Q2 2026 versus $15.6 million in Q1 2026. Adjusted SG&A(1) decreased $0.1 million to $9.1 million in Q2 2026 versus $9.2 million in Q1 2026.

▪Net income from continuing operations decreased $12.9 million to $(10.5) million in Q2 2026 versus $2.4 million in Q1 2026 primarily due to $5.0 million of accelerated trademark amortization related to our brand integration and a $10.5 million decrease in other non-operating income related to the non-cash revaluation of transaction earn-out liabilities.

▪Adjusted EBITDA(1) was $7.9 million in Q2 2026 versus $6.4 million in Q1 2026. Adjusted EBITDA margin rose to 10.9% in Q2 2026 versus 9.5% in Q1 2026. The 140 basis points increase in Adjusted EBITDA margin versus Q1 2026 was driven by the increase in Clinical gross margin and the mix shift to Clinical partially offset by the reduction in Logistics gross margin.

▪Cash flow from operating activities was $5.7 million in Q2 2026. In Q2 2026, the $2.2 million difference between Adjusted EBITDA and operating cash flow was driven primarily by the $1.7 million increase in working capital related to the timing of expenses.

▪Capital expenditures of $2.8 million in Q2 2026 were driven primarily by aircraft capitalized maintenance.

▪Free Cash Flow, before aircraft and engine acquisitions(1) was $2.9 million in Q2 2026.

▪Ended Q2 2026 with $22.8 million in cash and short term investments.

Business Highlights and Recent Updates

▪In late April 2026, we completed the acquisition of Ohio Valley Perfusion Associates, a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania, strengthening our cardiac care footprint in the region.

▪In early June 2026, we completed the acquisition of Louisville Perfusion Services ("LPS"), a regional provider of perfusion and blood management services to cardiac surgery programs in Kentucky.

▪In late June 2026, we completed the acquisition of Heart and Lung Transplant National Recovery Program (“HLT-NRP”), a provider of transplant surgical recovery services in the United States. HLT-NRP strengthens and adds scale to our organ recovery platform by increasing our network of experienced transplant surgeons available to complete recoveries, especially in key markets such as Florida and California.

▪In late July 2026, we signed an agreement to take over Statline's Transplant Center Organ Placement customer relationships on a rolling basis over the next year, bringing us long-term contracted attachment points with up to eight new customers that we believe could lead to incremental clinical or logistics business over time.

Financial Outlook

Today, we are updating our 2026 guidance:

▪Revenue of $285-295 million (previously: $260-275 million)

▪Adjusted EBITDA(2) of $33-35 million (previously: $29-33 million)

▪Free cash flow, before aircraft and engine acquisitions(2) of: $15-22 million (previously: $15-22 million)

Pro forma, assuming all acquisitions completed in 2026 closed on January 1 2026, our 2026 revenue and Adjusted EBITDA guidance would be approximately:

▪Revenue of $295-305 million

▪Adjusted EBITDA(2) of $36-38 million

Conference Call

The Company will conduct a conference call starting at 8:00 a.m. ET on August 4, 2026 to discuss the results for the second quarter ended June 30, 2026.

A live audio-only webcast of the call may be accessed from the Investor Relations section of the Company’s website at https://ir.stratacritical.com/. An archived replay of the call will be available on the Investor Relations section of the Company's website for one year.

(2) We have not reconciled the forward-looking Adjusted EBITDA and free cash flow, before aircraft and engine acquisitions guidance included above to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are, with respect to Adjusted EBITDA, incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings, and with respect to free cash flow, before aircraft and engine acquisitions, changes in operating assets and liabilities. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.

Use of Non-GAAP Financial Information

Strata believes that the non-GAAP measures discussed below, viewed in addition to and not in lieu of our reported U.S. generally accepted accounting principles ("GAAP") results, provide useful information to investors by providing a more focused measure of operating results, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. Adjusted EBITDA, Adjusted SG&A, Free Cash Flow, Free Cash Flow before aircraft and engine acquisitions, and Clinical revenue, excluding acquisitions, have all been reconciled to the nearest GAAP measure in the tables within this press release.

Adjusted EBITDA – Strata reports Adjusted EBITDA, which is a non-GAAP financial measure. Strata defines Adjusted EBITDA as net income (loss) from continuing operations adjusted to exclude: (1) depreciation and amortization; (2) stock-based compensation; (3) change in fair value of warrant liabilities and other assets and liabilities; (4) interest income and expense; (5) income tax; (6) impairment of intangible assets or property and equipment; and (7) certain other non-recurring items that management does not believe are indicative of the Company's ongoing operating performance and would impact the comparability of results between periods.

Adjusted SG&A – Strata defines Adjusted selling, general and administrative ("SG&A") expenses as SG&A adjusted to exclude: (1) depreciation; (2) stock-based compensation; (3) impairment of property and equipment; and (4) other non-cash items and certain other non-recurring items that management does not believe are indicative of the Company's ongoing operating performance that would impact the comparability of results between periods.

Free Cash Flow, and Free Cash Flow before aircraft and engines acquisitions – Strata defines Free Cash Flow as net cash provided by / (used in) operating activities less capital expenditures and capitalized software development costs (net of proceeds from disposals). Free Cash Flow before aircraft and engines acquisitions is defined as Free Cash Flow excluding cash outflows related to aircraft and engines acquisitions. Strata believes these measures provide valuable insights into the Company's cash-generating capacity. In particular, Free Cash Flow before aircraft and engines acquisitions highlights the cash generated by Strata's continuing operations prior to the impact of aircraft and engines acquisitions, which are discretionary and strategic in nature.

Clinical revenue, excluding Clinical acquisitions that closed in Q2 2026 – Strata defines Clinical revenue, excluding Clinical acquisitions that closed in Q2 2026, as total Clinical revenue, including Transplant Clinical and Other Clinical revenue, less revenue attributable to businesses acquired during the period presented. Strata believes this measure is useful to investors because it facilitates the evaluation of organic period-over-period growth in the Clinical segment by excluding growth attributable to acquired businesses.

Financial Results

STRATA CRITICAL MEDICAL, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share data, unaudited)


	June 30, 2026		December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	16,317	$	30,968
Restricted cash	264		264
Accounts receivable, net of allowance of $1,058 and $1,066 at June 30, 2026 and December 31, 2025, respectively	43,407		39,958

Short-term investments	6,436		30,263
Prepaid expenses and other current assets	54,586		24,739

Total current assets	121,010		126,192

Non-current assets:
Property and equipment, net	40,704		36,444

Intangible assets, net	60,008		47,502
Goodwill	106,946		88,210
Operating right-of-use asset	3,940		3,107

Other non-current assets	90		24,017

Total assets	$	332,698	$	325,472

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses	$	18,381	$	19,142

Operating lease liability, current	1,054		652
Other current liabilities	26,344		—

Total current liabilities	45,779		19,794

Non-current liabilities:
Warrant liability	—		1,530
Operating lease liability, non-current	3,201		2,655
Deferred tax liability	271		348
Other non-current liabilities	4,129		22,073

Total liabilities	53,380		46,400



Stockholders' Equity
Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	—		—
Common stock, $0.0001 par value; 400,000,000 authorized; 88,466,806 and 86,702,183 shares issued at June 30, 2026 and December 31, 2025, respectively	7		7
Additional paid in capital	433,224		424,616
Accumulated other comprehensive income	—		—
Accumulated deficit	(153,913)		(145,551)
Total stockholders' equity	279,318		279,072

Total liabilities and stockholders' equity	$	332,698	$	325,472

STRATA CRITICAL MEDICAL, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share data, unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Revenue	$	72,506	$	45,108	$	139,890	$	81,056
Cost of revenue	57,291		36,101		110,558		64,996
Gross profit	15,215		9,007		29,332		16,060

Operating expenses
Selling, general and administrative	13,996		13,292		29,601		25,622
Amortization of intangible assets	6,627		356		8,113		764
Total operating expenses	20,623		13,648		37,714		26,386

Operating loss from continuing operations	(5,408)		(4,641)		(8,382)		(10,326)

Other non-operating income (loss)
Interest income, net	331		1,155		804		2,476
Change in fair value of warrant liabilities	71		77		1,530		2,829
Change in fair value of assets and other liabilities	(5,510)		—		(2,066)		—


Total other non-operating income (loss)	(5,108)		1,232		268		5,305

Loss from continuing operations before income taxes	(10,516)		(3,409)		(8,114)		(5,021)

Income tax expense from continuing operations	—		—		—		—
Net loss from continuing operations	(10,516)		(3,409)		(8,114)		(5,021)
Net loss from discontinued operations	—		(334)		(248)		(2,215)
Net loss	$	(10,516)	$	(3,743)	$	(8,362)	$	(7,236)

Basic and diluted earnings (loss) per share
Continuing operations	$	(0.12)	$	(0.04)	$	(0.10)	$	(0.06)
Discontinued operations	—		(0.01)		—		(0.03)
Total basic and diluted earnings (loss) per share	$	(0.12)	$	(0.05)	$	(0.10)	$	(0.09)






Weighted-average number of shares outstanding:
Basic	86,213,930		81,297,402		85,770,897		80,598,483
Diluted	86,213,930		81,297,402		85,770,897		80,598,483

STRATA CRITICAL MEDICAL, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands, unaudited)


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025			2026		2025
Cash Flows From Operating Activities:
Net loss	$	(10,516)	$	(3,743)		$	(8,362)	$	(7,236)
Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Change in gain on sale of business	—		—			344		—
Depreciation and amortization	8,515		1,776			11,575		3,473
Stock-based compensation	3,706		5,349			8,741		9,566
Change in fair value of warrant liabilities	(71)		(77)			(1,530)		(2,829)
Change in fair value of other assets and liabilities	5,510		—			2,066		—








Accretion of interest income on held-to-maturity securities	(181)		(785)			(446)		(1,508)
Deferred tax expense (benefit)	(19)		21			(96)		4
Non-cash capital contribution	333		—			333		—
Other(1)	99		335			126		428


Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(577)		(3,904)			(194)		(1,650)
Accounts receivable	(666)		(6,257)			(517)		(6,777)
Other non-current assets	(1)		61			77		74
Operating right-of-use assets/lease liabilities	42		(31)			115		(61)
Accounts payable and accrued expenses	(487)		3,192			(2,645)		914
Deferred revenue	(12)		999			(15)		2,292
Other	12		—			—		—
Net cash provided by / (used in) operating activities (includes discontinued operations)	5,687		(3,064)			9,572		(3,310)

Cash Flows From Investing Activities:

Acquisitions, net of cash acquired	(34,823)		—			(34,823)		—
Cash transfer related to sale of business	—		—			(290)		—
Capitalized software development costs	(314)		(429)			(616)		(961)
Purchase of property and equipment, net of proceeds from disposal	(2,490)		(2,235)			(7,669)		(4,849)


Purchase of held-to-maturity investments	(6,254)		(12,206)			(6,254)		(96,403)
Proceeds from maturities of held-to-maturity investments	—		43,550			30,500		151,300




Net cash (used in) / provided by investing activities (includes discontinued operations)	(43,881)		28,680			(19,152)		49,087

Cash Flows From Financing Activities:
Proceeds from the exercise of common stock options	3		14			55		74
Taxes paid related to net share settlement of equity awards	(4,206)		(1,151)			(4,788)		(5,457)

Payments for debt issuance costs	(9)		—			(338)		—



Net cash used in financing activities (includes discontinued operations)	(4,212)		(1,137)			(5,071)		(5,383)

Effect of foreign exchange rate changes on cash balances	—		151			—		277

Net (decrease) / increase in cash and cash equivalents and restricted cash	(42,406)		24,630			(14,651)		40,671
Cash and cash equivalents and restricted cash - beginning	58,987		35,688			31,232		19,647
Cash and cash equivalents and restricted cash - ending	$	16,581	$	60,318		$	16,581	$	60,318

Reconciliation to condensed consolidated balance sheets (includes discontinued operations)
Cash and cash equivalents	$	16,317	$	58,754		$	16,317	$	58,754
Restricted cash	264		1,564			264		1,564
Total cash and cash equivalents and restricted cash	$	16,581	$	60,318		$	16,581	$	60,318

Supplemental cash flow information
Cash paid for:

Income Taxes paid	$	93	$	23		$	93	$	23
Non-cash investing and financing activities:



New leases under ASC 842 entered into during the period	$	—	$	592		$	1,317	$	1,200

Common stock issued for acquisition	4,267		—			4,267		—
Consideration payable in other current liabilities	2,950		—			2,950		—
Purchases of property and equipment and capitalized software in accounts payable and accrued expenses	(102)		(105)			59		234

(1) Prior year amounts have been updated to conform to current period presentation.

Key Metrics and Non-GAAP Financial Information

RECONCILIATION OF TOTAL SG&A TO ADJUSTED SG&A EXPENSE

(in thousands except percentages, unaudited)


	Three Months Ended June 30,						Three Months Ended March 31,			Six Months Ended June 30,
	2026			2025			2026			2026			2025

Total Selling, general and administrative	$	13,996		$	13,292		$	15,605		$	29,601		$	25,622
Adjustments to reconcile SG&A to Adjusted SG&A
Subtract:
Depreciation	101			15			67			168			76
Stock-based compensation	3,706			4,917			5,035			8,741			8,726
Legal expenses and regulatory advocacy fees(1)	(83)			345			209			126			703

Contingent consideration compensation (earn-out)(2)	333			—			—			333			—
M&A transaction costs and integration of the acquired company(3)	652			17			650			1,302			34
Reorganization and rebranding costs related to the sale of the Passenger business(4)	172			—			419			591			—
Corporate staff costs included in the sold Passenger business(5)	—			605			—			—			1,298
Other	—			—			11			11			—
Adjusted SG&A	$	9,115		$	7,393		$	9,214		$	18,329		$	14,785
Adjusted SG&A as a percentage of Revenue	12.6		%	16.4		%	13.7		%	13.1		%	18.2		%

(1) For the three months ended June 30, 2026, includes the reversal of a provision that had previously been adjusted in the calculation of Adjusted EBITDA, partially offset by legal fees relating to one specific litigation. For the six months ended June 30, 2026, includes the settlement fees related to one legal matter and legal fees relating to one specific litigation, partially offset by the reversal of a provision that had previously been adjusted in the calculation of Adjusted EBITDA. For the three months ended March 31, 2026, mainly includes settlement fees related to one specific legal matter. For the three and six months ended June 30, 2025, comprised of legal fees related to the Drulias class action lawsuit which the parties entered into a Stipulation of Settlement to fully resolve the matter in December 2025. We consider those matters to be non-recurring and not representative of the legal and regulatory advocacy costs typically incurred in the ordinary course of business.

(2) Represents contingent consideration in connection with the Keystone acquisition, where part of the Seller earnout was allocated to a vendor.

(3) For the three and six months ended June 30, 2026, and the three months ended March 31, 2026, consists of M&A transaction costs (including legal fees and professional fees related to financial, legal, and tax due diligence); and costs of integrating Keystone into a public company environment, including enterprise resource planning migration and software development costs to enhance its internally developed software to meet internal control standards.

(4) For the three and six months ended June 30, 2026, and the three months ended March 31, 2026, consists of rebranding costs related to the decommissioning of the Blade brand and the introduction of the Strata brand; one-time reorganization costs related to the restructuring of Strata headquarters staff following the transfer of certain positions to Joby Aviation; and software application costs incurred to separate our software from the Passenger platform.

(5) Represents corporate staff costs related to employees who transferred to Joby Aviation following the sale of the Passenger business on August 29, 2025. This adjustment is intended to enhance period-to-period comparability by excluding from all periods, costs associated with transferred employees whose corporate functions were not replaced. Under U.S. GAAP (ASC 205-20), these costs were required to remain in continuing operations prior to the divestiture because they were not directly attributable to discontinued operations.

RECONCILIATION OF NET INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED EBITDA

(in thousands except percentages, unaudited)


	Three Months Ended June 30,						Three Months Ended March 31,			Six Months Ended June 30,
	2026			2025			2026			2026			2025
Net loss from continuing operations	$	(10,516)		$	(3,409)		$	2,402		$	(8,114)		$	(5,021)
Add (deduct):
Depreciation and amortization	8,515			1,223			3,060			11,575			2,447
Stock-based compensation	3,706			4,917			5,035			8,741			8,726
Change in fair value of warrant liabilities	(71)			(77)			(1,459)			(1,530)			(2,829)
Change in fair value of assets and other liabilities	5,510			—			(3,444)			2,066			—

Interest income, net	(331)			(1,155)			(473)			(804)			(2,476)

Legal expenses and regulatory advocacy fees(1)	(83)			345			209			126			703



Contingent consideration compensation (earn-out)(2)	333			—			—			333			—

M&A transaction costs and integration of the acquired company(3)	652			17			650			1,302			34
Reorganization and rebranding costs related to the sale of the Passenger business(4)	172			—			419			591			—
Corporate staff costs included in the sold Passenger business(5)	—			605			—			—			1,298
Other	—			—			11			11			—




Adjusted EBITDA	$	7,887		$	2,466		$	6,410		$	14,297		$	2,882

Adjusted EBITDA as a percentage of revenue	10.9		%	5.5		%	9.5		%	10.2		%	3.6		%

(2) Represents contingent consideration in connection with the Keystone acquisition, where part of the Seller earnout was allocated to a vendor.

RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW MEASURES

(in thousands, unaudited)


	Three Months Ended June 30, 2026
Net cash provided by operating activities	$	5,687
Capitalized software development costs	(314)


Purchase of property and equipment, net of proceeds from disposal	(2,490)

Free cash flow	$	2,883
Aircraft and engine acquisition capital expenditures(1)	—
Free cash flow before aircraft and engine acquisitions	$	2,883

(1) Represents capital expenditures for aircraft and engine acquisitions, excluding capitalized maintenance subsequent to initial acquisition.

SEQUENTIAL QUARTER COMPARISON

(in thousands except percentages, unaudited)


	Three Months Ended June 30,	Three Months Ended March 31,
		2026			2026			% Change



Clinical revenue:
Transplant Clinical		$	12,521		$	9,839		27.3	%
Acquisitions		338			—			NM(1)
Transplant Clinical, excluding acquisitions		$	12,183		$	9,839		23.8	%

Other Clinical		$	11,745		$	9,946		18.1	%
Acquisitions		1,149			—			NM(1)
Other Clinical, excluding acquisitions		$	10,596		$	9,946		6.5	%

Total Clinical		$	24,266		$	19,785		22.6	%
Acquisitions		1,487			—			NM(1)
Total Clinical, excluding acquisitions		$	22,779		$	19,785		15.1	%

Clinical gross profit /margin:
Clinical gross profit		$	6,327		$	4,952		27.8	%
Clinical gross margin		26.1		%	25.0		%	110	bps


Net (loss) income from continuing operations		$	(10,516)		$	2,402		(537.8)	%

(1) Not meaningful.

About Strata Critical Medical

Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.

Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.

For more information, visit www.srta.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", “anticipate”, “believe”, “could”, “continue”, “expect", “estimate”, “may”, “plan”, “outlook”, “future”, "target", and “project” and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Strata’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning Strata’s future plans and business strategies, financial and operating performance (including the discussion of financial outlook and guidance for 2026 and beyond), acquisition opportunities, results of operations, and industry environment and growth opportunities. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Strata’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: our continued net losses or failure to achieve or maintain profitability; our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestment of the Passenger business and acquisition and integration of Keystone; any future acquisitions or partnerships; harm to our reputation and brand; negative publicity, litigation, claims or regulatory scrutiny; our ability to provide high-quality customer support and maintain trusted relationships with customers; our reliance on contractual relationships with transplant centers, hospitals, Organ Procurement Organizations and strategic partners; adoption and effective utilization of our integrated clinical and logistics offerings by medical customers; competition; our dependence on the availability and utilization of organ donors and transplant volumes; insufficient reimbursement or funding for organ transport and related services; risks inherent in organ transportation operations; risks associated with ground transportation operations; advancements in preservation technology or alternative transport methods; aviation safety risks; the effects of climate change, extreme weather events or environmental developments affecting our operations; terrorist attacks, geopolitical conflict or security events affecting aviation or healthcare infrastructure; the

volatility in aircraft fuel availability or cost; our ability to obtain additional capital or financing; restrictions under our credit agreement; our ability to manage our growth; insurance market conditions; our dependence on key personnel and our ability to attract and retain qualified professionals; employment-related claims, workforce litigation or labor market challenges; our ability to maintain our company culture as we grow; fluctuations in financial results and the non-comparability of historical financial statements; risks associated with purchasing aircraft or evolving from an asset-light model; risks associated with directly operating aircraft; our reliance on maintaining efficient aircraft utilization to manage costs, operating efficiency and margins; changes in regulatory frameworks; our reliance on third-party aircraft operators; the availability of sufficient third-party aircraft capacity; workforce disruptions, operations interruptions or financial difficulties affecting third-party operators or service workers; risks arising from illegal, improper, or otherwise inappropriate operation of branded aircraft by third-party operators; our reliance on third-party cloud infrastructure, hosting providers and other technology vendors; interruptions, defects, failures or vulnerabilities in our technology systems or those of third-party providers; cybersecurity incidents, data breaches or misuse of artificial intelligence technologies; our ability to protect and enforce intellectual property rights; risks associated with our use of open-source software; our operations within highly regulated environments; the impact of any litigation or regulatory investigations that we may be subject to; our ability to comply with privacy, data protection, consumer protection and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses and maintain effective disclosure controls and procedures; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Strata undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

Contacts

Mathew Schneider
investors@srta.com

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Press Releases

EX-99.1 EX-99.1 605.2 KB

Strata Critical Medical (Nasdaq: SRTA) lifts 2026 revenue and EBITDA guidance

Rhea-AI Filing Summary

Positive

Negative

Filing Explained

8-K Event Classification

Key Figures

Key Terms

Earnings Snapshot

FAQ

How did Strata Critical Medical (SRTA) perform financially in Q2 2026?

What drove revenue growth for Strata Critical Medical (SRTA) in Q2 2026?

What is Strata Critical Medical’s (SRTA) 2026 financial guidance?

How profitable was Strata Critical Medical (SRTA) on an Adjusted EBITDA basis in Q2 2026?

What acquisitions did Strata Critical Medical (SRTA) complete around Q2 2026?

What is Strata Critical Medical’s (SRTA) cash and liquidity position after Q2 2026?

Filing Exhibits & Attachments

Press Releases

Other Documents